GROWTH FACTORS FOR PRODUCTION OF DEFINITIVE ENDODERM

• US 20090298178A1
• Filed: 06/03/2008
• Published: 12/03/2009
• Est. Priority Date: 06/03/2008
• Status: Abandoned Application

• Current Assignee: Kevin Allen D'Amour
• Original Assignee: Kevin Allen D'Amour
• Inventors: D'Amour, Kevin Allen
• Application Number:
  US12/132,437
• Publication Number:
  US 20090298178A1
• Time in Patent Office: Days
• US Class Current: 435/377
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/117 Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/19 Growth and differentiation factors [GDF]
• CPC Class Codes: C12N 2501/385 of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2501/70 Enzymes
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

Disclosed herein are methods for generating endoderm lineage type cells derived from human pluripotent cells, such as human embryonic stem cells, by using various agents including, but not limited to, GDF8, GDF11 and GSK-3beta inhibitors. Also disclosed herein are endoderm lineage cell populations or compositions, such as populations or compositions comprising definitive endoderm and/or other definitive endoderm-derived cell types.

Claims

1. A method for generating definitive endoderm, said method comprising:

providing an in vitro cell population comprising pluripotent human cells with a factor selected from the group consisting of GDF8, GDF11 and a combination of GDF8 and GDF11 in an amount sufficient to induce pluripotent human cells of said cell population to differentiate into definitive endoderm cells.

2. The method of claim 1, wherein at least 15% of said pluripotent cells differentiate into definitive endoderm cells.

3. The method of claim 1, wherein at least 25% of said pluripotent cells differentiate into definitive endoderm cells.

4. The method of claim 1, wherein at least 35% of said pluripotent cells differentiate into definitive endoderm cells.

5. The method of claim 1, wherein at least 50% of said pluripotent cells differentiate into definitive endoderm cells.

6. The method of claim 1, wherein at least 60% of said pluripotent cells differentiate into definitive endoderm cells.

7. The method of claim 1, wherein at least 75% of said pluripotent cells differentiate into definitive endoderm cells.

8. The method of claim 1, wherein at least 85% of said pluripotent cells differentiate into definitive endoderm cells.

9. The method of claim 1, wherein at least 95% of said pluripotent cells differentiate into definitive endoderm cells.

10. The method of claim 1, wherein at least 100 ng/ml GDF8 is provided.

11. The method of claim 1, wherein at least 100 ng/ml GDF11 is provided.

12. The method of claim 1, wherein at least 100 ng/ml of a combination of GDF8 and GDF11 is provided.

13. The method of claim 1 further comprising providing an agent which activates the Wnt3a signaling pathway.

14. The method of claim 13, wherein the agent is selected from the group consisting of Wnt3a, a GSK3 inhibitor, a combination of GSK3 inhibitors and a combination of Wnt3a and one or more GSK3 inhibitors.

15. The method of claim 13, wherein the agent comprises Wnt3a.

16. The method of claim 15, wherein the agent further comprises GSK3 inhibitor number 15.

17. The method of claim 13, wherein the agent comprises a GSK3 inhibitor.

18. The method of claim 17, wherein the GSK3 inhibitor is a pyridocarbazolo-cyclopentadienyl ruthenium complex or a dihydropyrimidine.

19. The method of claim 17, wherein the GSK3 inhibitor is GSK3 inhibitor number 15.

20. The method of claim 1, wherein the pluripotent human cells are not contacted with an activin.

21. The method of claim 1, wherein said pluripotent cells comprise embryonic stem cells.

22. The method of claim 1, wherein the pluripotent cells are non-recombinant cells.